Prevention of Restenosis Using the Gene for Cecropin Complexed with DOCSPER Liposomes under Optimized Conditions

Area of Science:

• Vascular biology
• Gene therapy
• Cardiovascular research

Background:

• Restenosis, or renarrowing of arteries, affects up to 30% of patients post-angioplasty.
• Smooth muscle cell proliferation drives neointima formation, a key factor in restenosis.
• Cecropins, antimicrobial peptides, exhibit antiproliferative effects and suppress neointimal formation.

Purpose of the Study:

• To evaluate the efficacy of novel liposome-mediated gene transfer of cecropin A for preventing arterial restenosis.
• To assess the in vivo gene delivery and retention of cecropin A in a porcine model.

Main Methods:

• A plasmid encoding pre-pro-cecropin A was complexed with advanced liposomes.
• Gene delivery was performed via needle injection catheter to the adventitia in a porcine arterial injury model.
• Plasmid retention in treated arteries was monitored for at least 21 days.

Main Results:

• New liposomes demonstrated effective gene transfer and plasmid retention for over 21 days.
• Optimized delivery conditions with new liposomes resulted in almost complete suppression of neointimal proliferation.
• This approach significantly improved upon previous attempts with first-generation liposomes.

Conclusions:

• In vivo gene transfer of cecropins using optimized liposomes is a highly effective strategy for preventing restenosis.
• This therapeutic approach holds significant promise for clinical application in post-angioplasty patients.